# MANNKIND CORP (MNKD) · Edgar & Edgarette company card

> Mannkind (MNKD) grew revenue 22.2% in FY2025 to $349 million, operating margin 11.1% against a -3.8% median for pharmaceutical preparations, equity -6.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 899460 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/MNKD) · [JSON](https://www.pops4.com/boards/company/MNKD.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $349M |
| Revenue growth, 1 year | 22.2% |
| Revenue growth per year | 46.7% |
| Operating margin | 11.1% (prior year 25.4%) |
| Net margin | 1.7% |
| Operating cash flow | $18M |
| Capital spending | $5M |
| Free cash flow | $14M |
| Cash | $75M |
| Long-term debt | $355M |
| Total assets | $792M |
| Total equity | −$51M |
| Equity ÷ assets | -6.4% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -11.89 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Beneish M: 0.38 (above the −1.78 line)
- Health Harbor boat: Weathered boat · two warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); revenue is hard to predict: its 80% range is ±27%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $349.0M (FY2025), total debt $354.6M. Experience: revenue up 22.2% on the year, up 46.7% a year over 4 years; operating margin 11.1%, down from 25.4%. Soundness: equity -6.4% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $356.5M and $619.1M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $310.1M to $715.9M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 11.1% against a -3.8% median; growth 22.2% against 13.7%.

Range logged 2026-10-30, receipt b99affc706e6af63, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 8-K · filed 2026-08-21 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/899460/000119312526361105/0001193125-26-361105-index.htm)
- 10-Q · filed 2026-08-05 · [filing](https://www.sec.gov/Archives/edgar/data/899460/000119312526335054/0001193125-26-335054-index.htm)
- 8-K · filed 2026-08-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/899460/000119312526335016/0001193125-26-335016-index.htm)
- 8-K · filed 2026-07-24 · 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/899460/000119312526316041/0001193125-26-316041-index.htm)
- 8-K · filed 2026-06-02 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/899460/000119312526252544/0001193125-26-252544-index.htm)
- 8-K · filed 2026-05-28 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/899460/000119312526243074/0001193125-26-243074-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000899460.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=899460

## Cite

POPS4, Edgar & Edgarette: MANNKIND CORP (MNKD) company card, from the company's own SEC filings, accessed 2026-11-02, https://www.pops4.com/boards/company/MNKD. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.